SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...
Art Pappas joins a Venture Capital Panel at BioContactQuébec 2012 on October 3 in Quebec City.
News | 08. 14. 2012
Art Pappas joins a Venture Capital Panel at BioContactQuébec 2012 on October 3 in Quebec City.
